Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
LONDON - Ananda Pharma PLC (AQSE:ANA, OTCQB: ANANF) announced Monday that the final participant has received their last dose in its Phase 1 pharmacokinetic study of MRX1, the company’s cannabidiol formulation.
The trial, which enrolled 19 participants in Melbourne, Australia, was designed to evaluate the pharmacokinetic profile, safety, and tolerability of MRX1. Final safety and tolerability results are expected in the fourth quarter of 2025, with complete pharmacokinetic results anticipated in the first quarter of 2026.
During the six months ended July 31, 2025, Ananda reported a loss of £1.95 million before tax, compared to a loss of £1.21 million in the same period last year. The company’s net assets stood at £295,383 at the end of the period.
Ananda has manufactured 40 liters of MRX1 under Good Manufacturing Practices for use across its clinical trials, representing the first half of the required volume for its planned chemotherapy-induced peripheral neuropathy (CIPN) and endometriosis trials.
The company expects to receive ethics approvals for both the CIPN and endometriosis trials before year-end, with recruitment to begin shortly thereafter. These trials will run concurrently and independently of the Phase 1 study results.
In a strategic shift, Ananda terminated its relationship with a contractor supplying MRX2 and MRX2T formulations for epilepsy studies at University College London and Great Ormond Street Hospital in September. The company cited delays and intellectual property constraints as reasons for prioritizing resources on its lead MRX1 program.
During the period, Ananda appointed Viridian Capital as advisors to support its U.S. market focus and had its shares admitted to trading on the OTC exchange in New York. The company also added three former pharmaceutical executives as advisors, including two former GW Pharmaceuticals senior executives.
This information is based on Ananda Pharma’s unaudited interim results statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.